Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Change in Receivables: 2019-2023

Historic Change in Receivables for ADC Therapeutics (ADCT) over the last 2 years, with Dec 2023 value amounting to $4.0 million.

  • ADC Therapeutics' Change in Receivables fell 90.65% to $4.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$47.8 million, marking a year-over-year decrease of 211.78%. This contributed to the annual value of -$4.8 million for FY2024, which is 90.02% up from last year.
  • ADC Therapeutics' Change in Receivables amounted to $4.0 million in Q4 2023, which was up 248.18% from -$2.7 million recorded in Q3 2023.
  • Over the past 5 years, ADC Therapeutics' Change in Receivables peaked at $42.7 million during Q4 2022, and registered a low of -$48.9 million during Q1 2023.
  • In the last 3 years, ADC Therapeutics' Change in Receivables had a median value of -$8,118 in 2021 and averaged -$3.5 million.
  • As far as peak fluctuations go, ADC Therapeutics' Change in Receivables surged by 241.53% in 2022, and later plummeted by 1,410,977.09% in 2023.
  • Over the past 4 years, ADC Therapeutics' Change in Receivables (Quarterly) stood at $191,958 in 2019, then reached -$30.2 million in 2021, then surged by 241.53% to $42.7 million in 2022, then tumbled by 90.65% to $4.0 million in 2023.
  • Its Change in Receivables stands at $4.0 million for Q4 2023, versus -$2.7 million for Q3 2023 and -$188,000 for Q2 2023.